Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerhard Ehninger

Showing results (341-350 of 403) with videos related to

Pageof 41
Sort By:
Haematologica|December 9, 2017
Constitutional <i>SAMD9L</i> mutations cause familial myelodysplastic syndrome and transient monosomy 7Victor B Pastor, Sushree S Sahoo, Jessica Boklan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2017
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE TrialJan Moritz Middeke, Regina Herbst, Stefani Parmentier, et al.
Blood|December 31, 2011
Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor geneShuchi Agrawal-Singh, Fabienne Isken, Konstantin Agelopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trialHubert Serve, Utz Krug, Ruth Wagner, et al.
Haematologica|January 19, 2019
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantationNico Gagelmann, Diderik-Jan Eikema, Matthias Stelljes, et al.
Haematologica|November 5, 2017
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow TransplantationChristoph Schmid, Liesbeth C de Wreede, Anja van Biezen, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
British Journal of Haematology|January 16, 2016
TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantationJan M Middeke, Sylvia Herold, Elke Rücker-Braun, et al.
Blood Advances|January 4, 2018
Haploidentical transplant in patients with myelodysplastic syndromeMarie Robin, Raphael Porcher, Fabio Ciceri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trialChristoph Röllig, Martin Bornhäuser, Michael Kramer, et al.
Pageof 41

Showing results (341-350 of 403) with videos related to

Sort By:
Pageof 41
Haematologica|December 9, 2017
Constitutional <i>SAMD9L</i> mutations cause familial myelodysplastic syndrome and transient monosomy 7Victor B Pastor, Sushree S Sahoo, Jessica Boklan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2017
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE TrialJan Moritz Middeke, Regina Herbst, Stefani Parmentier, et al.
Blood|December 31, 2011
Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor geneShuchi Agrawal-Singh, Fabienne Isken, Konstantin Agelopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trialHubert Serve, Utz Krug, Ruth Wagner, et al.
Haematologica|January 19, 2019
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantationNico Gagelmann, Diderik-Jan Eikema, Matthias Stelljes, et al.
Haematologica|November 5, 2017
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow TransplantationChristoph Schmid, Liesbeth C de Wreede, Anja van Biezen, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
British Journal of Haematology|January 16, 2016
TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantationJan M Middeke, Sylvia Herold, Elke Rücker-Braun, et al.
Blood Advances|January 4, 2018
Haploidentical transplant in patients with myelodysplastic syndromeMarie Robin, Raphael Porcher, Fabio Ciceri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trialChristoph Röllig, Martin Bornhäuser, Michael Kramer, et al.
Pageof 41